RxDoctor Payments Data

Sounick Haldar, MD

Internal Medicine · Birmingham, ALNPI 1578906939

Payments from drug & device makers

$592in general payments, 2019–2025

Across 15 payments — averaging $39.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$253
  • Gilead$151
  • Corcept Therapeutics$47
  • Lilly USA, LLC$35
  • Bayer$33
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$23
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$592100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$592 in reported general payments places this provider in the 55th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$4,102
Medicare patients
25
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol48$57,712
EliquisApixaban19$26,024
TrulicityDulaglutide15$24,630
Atorvastatin Calcium240$1,989
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,953
Telmisartan49$1,940
Amlodipine Besylate162$1,032
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic13$686
Omeprazole45$653
Levothyroxine Sodium37$586
Losartan Potassium45$564
Lisinopril79$550
Albuterol Sulfate HfaAlbuterol Sulfate27$541
Chlorthalidone19$444
Pravastatin Sodium25$435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$253$57,71248 claims
PfizerEliquis$14$26,02419 claims
Lilly USA, LLCTrulicity$35$24,63015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →